Windtree Therapeutics

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No. 11,583,540, providing expanded patent coverage for istaroxime …

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office Read More


Passage Bio

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) recently announced updated clinical data from Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis (GM1), presented Friday …

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 Read More